Screener
Monte Rosa Therapeutics, Inc. GLUE Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Monte Rosa Therapeutics, Inc.’s reported figures.
Based on trailing twelve months.
The source filing: Monte Rosa Therapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:09 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336711
FAQ
- What is Monte Rosa Therapeutics, Inc.'s return on equity?
- Monte Rosa Therapeutics, Inc. (GLUE) reported return on equity of -42.7% in Q2 2026.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s return on equity?
- Over 2 years (2022 to 2025), Monte Rosa Therapeutics, Inc.'s return on equity has grown at a -30.5% compound annual growth rate (CAGR), from -35.1% to -16.9%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.
Ask your AI about Monte Rosa Therapeutics, Inc.'s return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude